Ortek Therapeutics
This article was originally published in The Tan Sheet
Executive Summary
Garden City, N.Y. firm to begin a U.S. trial by year end examining the effects of Cavistat on xerostomia (dry mouth) induced caries. Cavistat, which Ortek licenses from the State University of New York at Stonybrook, is a patented combination of arginine, calcium and a "cariostatic anion" thought to remineralize teeth. Ortek may launch a dentifrice containing the ingredient next year; the firm also is exploring marketing partnerships with larger companies. A 12-week, 100-subject trial already has been conducted showing Cavistat to be effective in treating tooth sensitivity, and another 750-subject caries study taking place in South America is scheduled to be completed in roughly a year